Evaluation of 99mTc-3PRGD2 integrin receptor imaging in hepatocellular carcinoma tumour-bearing mice: comparison with 18F-FDG metabolic imaging

Influence of spill-over for 99mTc images and the effect of scatter correction for dual-isotope simultaneous acquisition with 99mTc and 18F using small-animal SPECT-PET/CT system

A dual-isotope simultaneous acquisition (DISA) of 99mTc and 18F affects the image quality of 99mTc by crosstalk and spill-over from 18F. We demonstrated the influence of spill-over and crosstalk on image quality and its correction effect for DISA SPECT with 99mTc and 18F. A fillable cylindrical chamber of 30 mm with NEMA-NU4 image quality phantom was filled with 99mTc only or a mixed 99mTc and 18F solution (C100). Two small-region chambers were filled with 99mTc only or a mixed 99mTc and 18F solution made at half the radioactivity concentration of C100 (C50) and non-radioactive water (C0). The 18F/99mTc ratio for DISA was set at approximately 0.4-12. Two types of 99mTc transverse images with and without scatter correction (SC and nonSC) were created. The 99mTc images of single-isotope acquisition (SIA) were created as a reference. The DISA/SIA ratio and contrast of 99mTc were compared between SIA and DISA. Although the DISA/SIA ratios with nonSC of C100, C50 and C0 gradually increased with increasing 18F/99mTc ratio, it was nearly constant by SC. The contrasts of C100 and C50 were similar to a reference value for both nonSC and SC. In conclusion, DISA images showed lower image quality as the 18F/99mTc ratio increased. The image quality in hot-spot regions such as C100 and C50 was improved by SC, whereas cold-spot regions such as C0 could not completely remove the influence of spill-over even with SC.

Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma

Liver cancer is one of the leading causes of cancer deaths worldwide. Among all primary liver cancers, hepatocellular carcinoma (HCC) is the most common type, representing 75%‐85% of all primary liver cancer cases. Median survival following diagnosis of HCC is approximately 6 to 20 months due to late diagnosis in its course and few effective treatment options. Interventional therapy with minimal invasiveness is recognized as a promising treatment for HCC. However, due to the heterogeneity of HCC and the complexity of the tumor microenvironment, the long‐term efficacy of treatment for HCC remains a challenge in the clinic. Tumor microenvironment, including factors such as hypoxia, angiogenesis, low extracellular pH, interstitial fluid pressure, aerobic glycolysis, and various immune responses, has emerged as a key contributor to tumor residual and progression after locoregional treatment for HCC. New approaches to noninvasively assess the treatment response and assist in the clinical decision‐making process are therefore urgently needed. Molecular imaging tools enabling such an assessment may significantly advance clinical practice by allowing real‐time optimization of treatment protocols for the individual patient. This review discusses recent advances in the application of molecular imaging technologies for noninvasively assessing changes occurring in the microenvironment of HCC after locoregional treatment.

Role of [99mTc]Tc-Galacto-RGD2 SPECT/CT in identifying metastatic differentiated thyroid carcinoma after thyroidectomy and radioactive iodine therapy

PURPOSE

Integrin αvβ3, a member of the arginine-glycine-aspartate (RGD)-binding subfamily, is associated with tumor angiogenesis and metastasis. The aim of study is to investigate the clinical role of [^99mTc]Tc-Galacto-RGD₂ SPECT/CT in high-risk differentiated thyroid carcinoma (DTC) after thyroidectomy and radioactive iodine (RAI) therapy.

METHODS

Thirty-six patients with high-risk DTC (20 males, 16 females; mean age: 59.9 ± 16.6 y) who underwent thyroidectomy and RAI therapy were consecutively enrolled in this study. All patients underwent [^99mTc]Tc-Galacto-RGD₂ SPECT/CT and diagnostic ¹³¹I whole-body scan 6 months after the last RAI treatment. A region of interest (ROI) was drawn and the ratio of tumor/non-target (T/NT) was calculated. Per-patient and per-lesion analysis was performed to evaluate the diagnostic efficacy. The final diagnosis was confirmed by histopathology and follow-up. Integrin αvβ3, CD31, and Ki-67 expression in the tumor were also analyzed for evaluation of angiogenesis and proliferation.

RESULTS

Out of 36 patients, twenty-two had metastatic disease. By per-patient analysis, the area under the curve of [^99mTc]Tc-Galacto-RGD₂ SPECT/CT was marginally significantly higher than that of ¹³¹I whole-body scan and morphological imaging (P = 0.0034 and 0.0006). For per-lesion analysis, [^99mTc]Tc-Galacto-RGD₂ SPECT/CT identified 67 metastatic lymph nodes in 14 patients, 12 lung metastases in four patients, and 12 bone metastases in six patients; its sensitivity was significantly higher than that of ¹³¹I whole-body scan in detection of lymphatic (90.54% vs. 55.41%, P = 0.0124) and bone metastasis (92.31% vs. 30.77%, P = 0.046). The ratio of T/NT in metastatic lesions increased with the DTC upstaging.

CONCLUSIONS

[^99mTc]Tc-Galacto-RGD₂ SPECT/CT has high sensitivity in the detection of metastasis in high-risk DTC and further contributes to evaluation of tumor angiogenesis and radio‑iodine refractory status.